yingweiwo

Zonisamide (AD 810; CI 912)

Alias: AD-810; CI-912;AD810; CI912;AD 810; CI 912
Cat No.:V1645 Purity: ≥98%
Zonisamide (AD810; CI912;AD-810; CI-912),an antiepileptic drug, is a voltage-dependent sodium channel and T-type calcium channel blocker.
Zonisamide (AD 810; CI 912)
Zonisamide (AD 810; CI 912) Chemical Structure CAS No.: 68291-97-4
Product category: Sodium Channel
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
100mg
250mg
500mg
1g
10g
Other Sizes

Other Forms of Zonisamide (AD 810; CI 912):

  • Zonisamide-d4 (zonisamide d4)
  • Zonisamide sodium (AD 810; CI 912)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Zonisamide (AD810; CI912; AD-810; CI-912), an antiepileptic drug, is a voltage-dependent sodium channel and T-type calcium channel blocker. Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH).

Biological Activity I Assay Protocols (From Reference)
ln Vitro
By inhibiting apoptosis, zonisamide (10, 50, 100, and 200 μM; 24 h) improves the viability of SH-SY5Y cells[1]. In PD-cellular models, zonisamide (100 μM; 24 h) promotes neuroprotection. (PD: Parkinson's illness)(1). When proapoptotic molecules are reduced and MnSOD is upregulated (over-expression of MnSOD attenuates MPTP toxicity and shields cells from apoptosis), zonisamide (100 μM; 24 h) is introduced. Heart fibrosis and hypertrophy are inhibited in vitro by zonisamide (0.1, 0.3, 1 μM; 24 h)[3]. When Ang II is applied to NRCMs, zonisamide significantly boosts Hrd1 expression[3].
ln Vivo
In the FeCl3-induced chronic amygdalar seizures model, zonisamide (40 mg/kg; ip; once daily for 14 days) inhibits seizures[2]. ?In rats with abdominal aortic constriction (AAC), zonisamide (14, 28, 56 mg/kg; ip; once daily for 6 weeks) reduces cardiac hypertrophy and improves cardiac function[3]. ?In the hearts of AAC rats, zonisamide (14, 28, 56 mg/kg; ip; once daily for six weeks) increases Hrd1 expression and speeds up ERAD[3].
Cell Assay
Cell Viability Assay[1]
Cell Types: SH- SY5Y cells
Tested Concentrations: 10, 50, 100, 200 µM
Incubation Duration: 24 h
Experimental Results: Induced an increase of cell viability, and with the greatest effect being at 100 µM. demonstrated neuroprotective effect on SH-SY5Y cells (PD-cellular models) when at 100 µM.

Apoptosis Analysis[1]
Cell Types: SH-SY5Y cells
Tested Concentrations: 100 µM
Incubation Duration: 24 h
Experimental Results: demonstrated an effect of anti-apoptotic.

RT-PCR[3]
Cell Types: NRCMs and cardiac fibroblasts ( expose to Ang II for cardiomyocyte hypertrophy and fibrosis model)
Tested Concentrations: 0.1, 0.3, 1 μM
Incubation Duration: 24 h
Experimental Results: diminished the expression of atrial natriuretic factor (ANF) and cardiomyosin heavy chain β (β-MHC) but increased the expression of cardiac myosin heavy chain α (α-MHC) in NRCMs. diminished cardiac expression of the fibrosis-related gene Collagen 1A1 (Col1A1) in cardiac fibroblasts.

Western Blot Analysis[1]
Cell Types: SH-SY5Y cells
Tested Concentrations: 100 µM
Incubation Duration: 24 h
Experimental Results: decreased the pr
Animal Protocol
Animal/Disease Models: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures)[2].
Doses: 40 mg/kg
Route of Administration: intraperitoneal (ip)injection; single daily for 14 days.
Experimental Results: demonstrated activity of anti-seizures. Dramatically down-regulated GABA transporters GAT-1 in the hippocampus.

Animal/Disease Models: Adult male SD (Sprague-Dawley) rats (100-120 g; cardiac hypertrophy model)[3].
Doses: 14, 28, 56 mg/ kg
Route of Administration: intraperitoneal (ip)injection; single daily for 6 weeks.
Experimental Results: Dramatically attenuated cardiac hypertrophy and fibrosis. Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio. Markedly increased the expression of Hrd1 in the hearts of AAC rats.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Between 200 and 400 mg, zonisamide follows a dose-proportional pharmacokinetic profile. At concentrations higher than 800 mg, the Cmax and AUC increase in a disproportional manner, possibly due to zonisamide binding red blood cells. In healthy volunteers given 200 to 400 mg of zonisamide orally, peak plasma concentrations (Cmax) range between 2 and 5 µg/mL and are reached within 2–6 hours (Tmax). In healthy volunteers given 100 mg of zonisamide oral suspension, the Tmax ranged from 0.5 to 5 hours. Zonisamide has a high oral bioavailability (95%). The Tmax of zonisamide was delayed by food intake (4-6 hours); however, food has no effect on its bioavailability. Steady state is achieved 14 days after a stable dose is reached.
Zonisamide is mainly excreted as the parent drug and the glucuronide of a metabolite. Urine is the main route of zonisamide excretion, and only a small portion of this drug is excreted in feces. Following multiple doses of radiolabeled zonisamide, 62% of the dose was recovered in the urine, and 3% in feces by day 10. Of the excreted dose of zonisamide, 35% was recovered unchanged, 15% as N-acetyl zonisamide, and 50% as the glucuronide of 2–sulfamoylacetylphenol (SMAP).
Following a 400 mg oral dose, zonisamide has an apparent volume of distribution (V/F) of 1.45 L/kg.
In patients not taking enzyme-inducing antiepilepsy drugs (AEDs), the plasma clearance of oral zonisamide is approximately 0.30-0.35 mL/min/kg. In patients treated with AEDs, this value increases to 0.5 mL/min/kg. Renal clearance is approximately 3.5 mL/min after a single-dose of zonisamide. In red blood cells, the clearance of an oral dose of zonisamide is 2 mL/min.
Elimination: Renal: 62%, Fecal: 3%. Plasma clearance of zonisamide is approximately 0.30 to 0.35 mL/min/kg in patients not receiving concomitant therapy with enzyme-inducing anticonvulsants. Zonisamide clearance is increased to 0.5 mL/min/kg in patients concurrently receiving enzyme-inducing anticonvulsant medications.
In patients with creatinine clearance <20 mL/min, the area under the concentration-time curve (AUC) for zonisamide is increased by 35%.
Zonisamide is distributed to breast milk, cerebrospinal fluid, and erythrocytes. Concentration in erythrocytes is approximately 8 times higher than in plasma and the milk-to-plasma ratio is 0.93. The concentration of zonisamide in cerebrospinal fluid is approximately 76% of the concentration found in plasma.
Following a 200-400 mg oral zonisamide dose, peak plasma concentrations (range: 2-5 ug/mL) in normal volunteers occur within 2-6 hours. In the presence of food, the time to maximum concentration is delayed, occurring at 4-6 hours, but food has no effect on the bioavailability of zonisamide. Zonisamide extensively binds to erythrocytes, resulting in an eight-fold higher concentration of zonisamide in red blood cells (RBC) than in plasma. The pharmacokinetics of zonisamide are dose proportional in the range of 200-400 mg, but the Cmax and AUC increase disproportionately at 800 mg, perhaps due to saturable binding of zonisamide to RBC. Once a stable dose is reached, steady state is achieved within 14 days. ...The apparent volume of distribution (V/F) of zonisamide is about 1.45 L/kg following a 400 mg oral dose. Zonisamide, at concentrations of 1.0-7.0 ug/mL, is approximately 40% bound to human plasma proteins. Protein binding of zonisamide is unaffected in the presence of therapeutic concentrations of phenytoin, phenobarbital or carbamazepine.
Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite. ... Of the excreted dose, 35% was recovered as zonisamide, 15% as N-acetyl zonisamide, and 50% as the glucuronide of 2-sulfamoylacetyl phenol (SMAP)
Metabolism / Metabolites
Zonisamide metabolites are generated mainly by principally reductive and conjugative mechanisms. Oxidation reactions play a minor role in the metabolism of zonisamide. Zonisamide is metabolized by N-acetyl-transferases to form N-acetyl zonisamide and reduced to form the open ring metabolite, 2–sulfamoylacetylphenol (SMAP). The reduction of zonisamide to SMAP is mediated by CYP3A4. Zonisamide does not induce liver enzymes or its own metabolism.
... Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite. ... Zonisamide undergoes acetylation to form N-acetyl zonisamide and reduction to form the open ring metabolite, 2-sulfamoylacetyl phenol (SMAP). Of the excreted dose, 35% was recovered as zonisamide, 15% as N-acetyl zonisamide, and 50% as the glucuronide of SMAP. Reduction of zonisamide to SMAP is mediated by cytochrome p450 isozyme 3A4 (CYP3A4). Zonisamide does not induce its own metabolism.
Zonisamide undergoes acetylation to form N-acetyl zonisamide and reduction to form the open ring metabolite, 2-sulfamoylacetyl phenol (SMAP). ... Reduction of zonisamide to SMAP is mediated by cytochrome P450 isozyme 3A4 (CYP3A4). Zonisamide does not induce its own metabolism.
Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively.
Route of Elimination: Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite.
Half Life: 63 hours
Biological Half-Life
In plasma, the elimination half-life of zonisamide is approximately 63 hours. In red blood cells, it is approximately 105 hours.
Elimination /half-life/ in plasma: 63 hours; Elimination /half-life/ in erythrocytes: 105 hours.
Toxicity/Toxicokinetics
Hepatotoxicity
Prospective studies suggest that chronic zonisamide therapy may be accompanied by mild increases in serum alkaline phosphatase levels, but it has not been linked to significant increases in serum aminotransferase levels during treatment. Clinically apparent hepatotoxicity from zonisamide is rare, but several case reports of hepatic injury linked to zonisamide have been published. Zonisamide is typically used in combination with other anticonvulsants and its separate role in causing liver injury is often difficult to delineate. Zonisamide has been linked to a single case report of cholestatic hepatitis associated with vanishing bile duct syndrome that ultimately resolved. More commonly, zonisamide has been linked to cases of hypersensitivity (DRESS syndrome or Stevens-Johnson syndrome) with rash, fever, eosinophilia, renal failure and/or mild liver test abnormalities. In most instances, the hepatic injury was cholestatic and arose 3 to 8 weeks after starting therapy. Autoantibodies are usually not present. Interestingly, a similar cholestatic liver injury has been described in dogs receiving zonisamide.
Likelihood score: D (possible rare cause of clinically apparent liver injury).
Mechanism of Injury
The mechanism of zonisamide hepatotoxicity is unknown but is likely to be hypersensitivity. Cases of drug hypersensitivity to zonisamide have been linked to HLA-A*02:07 in Japanese subjects.
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Limited information indicates that maternal doses of zonisamide up to 400 mg daily produce high levels in milk and infant serum, but infant serum levels in neonates decrease during the first month of life while nursing. Although no adverse reactions have been reported in breastfed infants, the number of infants reported have been small. Alternative drugs are preferred, but if it must be given, monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger or exclusively breastfed infants and when using combinations of anticonvulsant drugs. Some clinicians recommend that mothers taking zonisamide only partially breastfeed in order to reduce the exposure of the infant to the drug and to consider monitoring infants’ serum zonisamide concentrations.[1]
◉ Effects in Breastfed Infants
A patient taking zonisamide 300 mg orally 3 times daily as well as other unspecified antipsychotics was followed at 0, 3, 14 and 30 days postpartum. Her infant exhibited no behavioral problems.[3]
Two infants were breastfed postpartum by their mothers. One was exclusively breastfed for 9 days postpartum, then breastfed twice daily and supplemented with formula 7 to 8 times daily. The maternal zonisamide dose was 300 mg (6.2 mg/kg) daily. On day 34, the infant was healthy, had gained weight and had experienced no observable adverse effects. The second infant was partially breastfed by a mother taking zonisamide 100 mg (2.1 mg/kg) daily. No adverse reactions were noted in the infant during the first 2 weeks postpartum, at which time breastfeeding was discontinued because of a low milk supply.[1]
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
At concentrations between 1.0 and 7.0 μg/mL, zonisamide is approximately 40% bound to human plasma proteins. The concentration of zonisamide is 8-fold higher in red blood cells than in plasma due to its ability to bind extensively to erythrocytes. The presence of therapeutic concentrations of phenytoin, phenobarbital, or carbamazepine does not affect zonisamide protein binding.
References
[1]. Kawajiri S, et al. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett. 2010 Sep 6;481(2):88-91.
[2]. Ueda Y, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6.
[3]. Wu Q, et al. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021 Oct;42(10):1587-1597.
[4]. De Simone G, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20.
Additional Infomation
Zonisamide is a 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. It has a role as an anticonvulsant, an antioxidant, a central nervous system drug, a protective agent and a T-type calcium channel blocker. It is a member of 1,2-benzoxazoles and a sulfonamide.
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.
Zonisamide is an Anti-epileptic Agent. The mechanism of action of zonisamide is as a Carbonic Anhydrase Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of zonisamide is by means of Decreased Central Nervous System Disorganized Electrical Activity.
Zonisamide is a new generation anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Zonisamide has not been associated with elevations in serum aminotransferase levels and clinically apparent drug induced liver disease has been reported with its use but is very rare.
Zonisamide is a sulfonamide derivative with an anticonvulsant property. The exact mechanism of action remains to be elucidated. Zonisamide appears to block sodium and calcium channels, thereby stabilizing neuronal membranes and suppressing neuronal hyper-synchronization. Although zonisamide shows affinity for the gamma-aminobutyric acid (GABA)/benzodiazepine receptor ionophore complex, it does not potentiate the synaptic activity of GABA. In addition, this agent also facilitates both dopaminergic and serotonergic neurotransmission.
Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.
A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
Drug Indication
Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.
FDA Label
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
Mechanism of Action
The mechanism of action by which zonisamide controls seizures has not been fully established. However, its antiepileptic properties may be due to its effects on sodium and calcium channels. Zonisamide blocks sodium channels and reduces voltage-dependent, transient inward currents, stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It affects T-type calcium currents, but has no effect on L-type calcium currents. Zonisamide suppresses synaptically-driven electrical activity by altering the synthesis, release, and degradation of neurotransmitters, such as glutamate, gamma-aminobutyric acid (GABA), dopamine, serotonin (5-hydroxytryptamine [5-HT]), and acetylcholine. Furthermore, it binds to the GABA/benzodiazepine receptor ionophore complex without producing changes in chloride flux. _In vitro_ studies have suggested that zonisamide does not affect postsynaptic GABA or glutamate responses, nor the neuronal or glial uptake of [3H]-GABA.
The exact method by which zonisamide exerts its anticonvulsant effect is unknown. Some in vitro studies suggest a blockade of sodium channels, with consequent stabilization of neuronal membranes and suppression of neuronal hypersynchronization, whereas other in vitro studies have shown zonisamide to suppress synaptically-driven electrical activity without affecting postsynaptic GABA or glutamate responses. It appears then, that zonisamide dose not potentiate the synaptic activity of GABA. Zonisamide also serves as a weak inhibitor of carbonic anhydrase.
Epileptiform discharges and behavioral seizures may be the consequences of excess excitation associated with the neurotransmitter glutamate, or from inadequate inhibitory effects associated with gamma-aminobutyric acid (GABA). Synaptic effects of these neurotransmitters are terminated by the action of transporter proteins that remove amino acids from the synaptic cleft. Excitation initiated by the synaptic release of glutamate is attenuated by the action of glial transporters glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1), and the neuronal transporter excitatory amino-acid carrier-1 (EAAC-1). GABA is removed from synaptic regions by the action of the transporters proteins GABA transporter-1 (GAT-1) and GABA transporter-3 (GAT-3). Albino rats with chronic, spontaneous recurrent seizures induced by the amygdalar injection of eCl3 were treated for 14 days with zonisamide (ZNS) (40 mg/kg, ip). Control animals underwent saline injection into the same amygdalar regions. Treatment control for both groups of intracerebrally injected animals was ip injection of equal volumes of saline. Western blotting was used to measure the quantity of glutamate and GABA transporters in hippocampus and frontal cortex. ZNS caused increase in the quantity of EAAC-1 protein in hippocampus and cortex and down regulation of the GABA transporter GAT-1. These changes occurred in both experimental and ZNS treated control animals. These data show that the molecular effect of ZNS, with up-regulation of EAAC-1 and decreased production of GABA transporters, should result in increased tissue and synaptic concentrations of GABA.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C8H8N2O3S
Molecular Weight
212.23
Exact Mass
212.025
CAS #
68291-97-4
Related CAS #
Zonisamide-d4;1020720-04-0;Zonisamide sodium;68291-98-5
PubChem CID
5734
Appearance
White needles from ethyl acetate
Density
1.5±0.1 g/cm3
Boiling Point
457.2±47.0 °C at 760 mmHg
Melting Point
275°C dec.
Flash Point
230.3±29.3 °C
Vapour Pressure
0.0±1.1 mmHg at 25°C
Index of Refraction
1.656
LogP
-0.1
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
2
Heavy Atom Count
14
Complexity
298
Defined Atom Stereocenter Count
0
SMILES
S(C([H])([H])C1C2=C([H])C([H])=C([H])C([H])=C2ON=1)(N([H])[H])(=O)=O
InChi Key
UBQNRHZMVUUOMG-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
Chemical Name
benzo[d]isoxazol-3-ylmethanesulfonamide
Synonyms
AD-810; CI-912;AD810; CI912;AD 810; CI 912
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 42 mg/mL (197.9 mM)
Water:<1 mg/mL
Ethanol: 5 mg/mL (23.6 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (9.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 1 mg/mL (4.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C).

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.7119 mL 23.5593 mL 47.1187 mL
5 mM 0.9424 mL 4.7119 mL 9.4237 mL
10 mM 0.4712 mL 2.3559 mL 4.7119 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06361446 RECRUITING Drug:Zonisamide 50 MG
Drug:Propranolol
Migraine Kafrelsheikh University 2024-03-29 Phase 3
NCT06374966 NOT YET RECRUITING Drug:Zonisamide Epilepsies,Partial Second Affiliated Hospital,
School of Medicine,
Zhejiang University
2024-04
NCT03034538 SUSPENDED Drug:Zonegran
Drug:Zonegran
Dyskinesias
Parkinson Disease
Parkinsonism
The Cooper Health System 2016-04-08 Phase 4
NCT05134857 RECRUITING Drug:Zonisamide
Drug:Placebo
Alcohol Use Disorder (AUD) Washington State University 2022-01-07 Phase 2
NCT02707965 COMPLETED Drug: Oxcarbazepine
Drug: Divalproex Sodium
Drug: Carbamazepine
Epilepsy Food and Drug Administration(FDA) 2017-06-08 Phase 1
Biological Data
  • Zonisamide alleviated cardiac hypertrophy and improved cardiac function in rats subjected to AAC. a Experimental protocol for AAC and termination of the experiment. b, c Representative M-mode images (left panel) and the transmitral filling pattern (right panel) in the sham (vehicle), AAC (vehicle), A+Z 14 (AAC+Z 14 mg · kg−1 · d−1), A+Z 28 (AAC+Z 28 mg · kg−1 · d−1) and A+Z 56 (AAC+Z 56 mg · kg−1 · d−1) groups. d–i Quantitative analysis of LVAW,S; LVAW,D; LVPW,S; LVPW,D; LVID,S; LVID,D; EF%; FS%; MV E/A; and HR in five groups in the 6th week after treatment with zonisamide or vehicle (n = 7). Data were analyzed by one-way ANOVA as the mean ± SEM. **P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. AAC. AAC(A) abdominal aorta constriction, Z Zonisamide, A+Z 14 AAC+Z 14 mg · kg−1 · d−1, A+Z 28 AAC+Z 28 mg · kg−1 · d−1, A+Z 56 AAC+Z 56 mg · kg−1 · d−1, LVAW,S the left ventricular end-systolic anterior wall thickness, LVAW,D the left ventricular end-diastolic anterior wall thickness, LVPW,S the left ventricular end-systolic posterior wall thickness, LVPW,D the left ventricular end-diastolic posterior wall thickness, LVID,S the left ventricular end-systolic internal dimension, LVID,D the left ventricular end-diastolic internal dimension, EF ejection fraction, FS fractional shortening, MV E/A the ratio of E-wave velocity to A-wave velocity, HR heart rate. Acta Pharmacol Sin . 2021 Oct;42(10):1587-1597.
  • Zonisamide reduced myocardial fibrosis and the heart weight-to-body weight ratio (HW/BW) in AAC rats. Rats in the sham (vehicle), AAC (vehicle), A+Z 14, A+Z 28, and A+Z 56 groups were treated with vehicle or zonisamide for 6 weeks. a Original heart images from different groups. b Quantitative analysis of the HW/BW (n = 7). c Representative H&E staining from hearts in different groups (n = 3) (scale bar = 50 μm). d Quantitative analysis of cardiomyocyte cell surface area (n = 3). e Representative Masson trichrome staining from hearts in different groups (n = 3) (scale bar = 50 μm). f Statistical results for fibrotic area in different groups (n = 3). Data were analyzed by one-way ANOVA as the mean ± SEM. **P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. AAC. Acta Pharmacol Sin . 2021 Oct;42(10):1587-1597.
  • Zonisamide inhibited cardiac hypertrophy and fibrosis in vitro. NRCMs and cardiac fibroblasts were incubated with zonisamide (0.1, 0.3, 1 μM dissolved in 0.1% DMSO) and Ang II for 24 h. a mRNA levels of ANF, β-MHC, and α-MHC in NRCMs and Collagen 1A1 in cardiac fibroblasts were assessed by RT-PCR (n = 5). b NRCMs were stained with phalloidin (phalloidin-tetramethylrhodamine isothiocyanate) and DAPI to evaluate cell surface area. c Quantitative analysis of cell surface area with ImageJ software (n = 4) (scale = 50 µm). Data were analyzed by one-way ANOVA. Values are presented as the mean ± SEM. *P < 0.05, **P < 0.01 vs. Con; #P < 0.05, ##P < 0.01 vs. Ang II. Acta Pharmacol Sin . 2021 Oct;42(10):1587-1597.
Contact Us